Unlocking the power of immunotherapy

RECENT NEWS

April 2018

Study assesses immunotherapies for precancerous cervical lesions, advanced disease

Published in Healio / HemOnc Today

[ READ MORE ]

March 2018

Q&A with Mark Leuchtenberger, CEO of IRX Therapeutics developing a New Immunotherapy Candidate containing Numerous Active Cytokine Components that Turn Cold Tumors Hot and is currently in Clinical Trials for Head and Neck and Breast Cancer

Published in CEOCFO Magazine

[ READ MORE ]

October 2017

The Challenge of Complex Biologics Development
Written by Ron Guido, VP of Regulatory Affairs, IRX Therapeutics

Published in Pharma Tech Outlook

[ READ MORE ]

IRX Therapeutics is a clinical-stage bioresearch company developing IRX-2, an important new immunotherapy candidate for cancer

IRX Therapeutics is a clinical-stage company developing novel immunotherapies focused on reducing the immune suppression that is seen in the cancer tumor microenvironment, restoring immune function, and activating a coordinated immune response against the tumor. The lead candidate, IRX-2, is a proprietary therapeutic containing numerous active cytokine components. Data collected to date indicates that IRX-2 acts to restore and activate a coordinated immune response against the tumor. IRX-2 is a proprietary therapeutic containing numerous active cytokine components, which restores and activates multiple immune cell types, including T cells, dendritic cells, and natural killer cells to recognize and destroy tumors. Currently, IRX-2 is being studied in an ongoing phase 2b clinical trial in patients with newly diagnosed stage II, III, and IVA squamous cell carcinoma of the head and neck (SCCHN) (INSPIRE) (clinicaltrials.gov NCT02609386) and in preoperative early stage breast cancer (ESBC) (clinicaltrials.gov NCT02950259).